Pros and cons of docetaxel used to treat metastatic hormone-sensitive prostate cancer: The cons

被引：0
|
作者：
Suzuki, Kazuhiro [1 ]
机构：
[1] Gunma Univ, Grad Sch Med, Dept Urol, Maebashi, Gunma, Japan
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
WS-1-2
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Postmenopausal hormone therapy: the pros and cons
    Rivera-Woll, LM
    Davis, SR
    INTERNAL MEDICINE JOURNAL, 2004, 34 (03) : 109 - 114
  • [32] Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy
    Yanagisawa, Takafumi
    Hata, Kenichi
    Narita, Shintaro
    Hatakeyama, Shingo
    Mori, Keiichiro
    Yata, Yuji
    Sano, Takayuki
    Otsuka, Takashi
    Hara, Shuhei
    Miyajima, Keiichiro
    Enei, Yuki
    Fukuokaya, Wataru
    Nakazono, Minoru
    Matsukawa, Akihiro
    Miki, Jun
    Habuchi, Tomonori
    Ohyama, Chikara
    Shariat, Shahrokh F.
    Kimura, Takahiro
    PROSTATE, 2023, 83 (06): : 563 - 571
  • [33] Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever
    Tsao, Che-Kai
    Galsky, Matthew D.
    Oh, William K.
    EUROPEAN UROLOGY, 2016, 70 (05) : 707 - +
  • [34] Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra
    Fizazi, K.
    Jenkins, C.
    Tannock, I. F.
    ANNALS OF ONCOLOGY, 2015, 26 (08) : 1660 - 1667
  • [35] Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy
    Yanagiswawa, T.
    Hata, K.
    Narita, S.
    Hatakeyama, S.
    Mori, K.
    Yata, Y.
    Sano, T.
    Otsuka, T.
    Hara, S.
    Miyajima, K.
    Enei, Y.
    Fukuokaya, W.
    Nakazono, M.
    Matsukawa, A.
    Miki, J.
    Habuchi, T.
    Ohyama, C.
    Shariat, S. F.
    Kimura, T.
    EUROPEAN UROLOGY, 2023, 83
  • [36] Cost-effectiveness of docetaxel in high-volume hormone-sensitive metastatic prostate cancer
    Beca, Jaclyn
    Majeed, Habeeb
    Chan, Kelvin K. W.
    Hotte, Sebastian J.
    Loblaw, Andrew
    Hoch, Jeffrey S.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2019, 13 (12): : 396 - 403
  • [37] Diagnosis and staging of metastatic hormone-sensitive prostate cancer
    Krausewitz, Philipp
    Ritter, Manuel
    Essler, Markus
    UROLOGIE, 2023, 62 (04): : 347 - 353
  • [38] Triple therapy in metastatic hormone-sensitive prostate cancer
    Tsaur, Igor
    Mirvald, Cristian
    Surcel, Cristian
    CURRENT OPINION IN UROLOGY, 2023, 33 (06) : 452 - 457
  • [39] Approval for Zytiga® in metastatic hormone-sensitive Prostate Cancer
    Junker, Annette
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 (03) : 152 - 152
  • [40] Modern treatment of metastatic hormone-sensitive prostate cancer
    Kuronya Zsofia
    Biro Krisztina
    Geczi Lajos
    Maraz Aniko
    ORVOSI HETILAP, 2018, 159 (41) : 1664 - 1671
12345